Literature DB >> 8601051

Obsessive-compulsive disorder in elderly patients.

C W Jackson1.   

Abstract

Obsessive-compulsive disorder (OCD) is a common illness which starts in young adulthood and persists into late life. OCD is associated with dysregulation of the serotonin system and may also be related to the dysregulation of dopamine. When OCD starts in an elderly patient, either an organic or a neurological diagnosis should be considered. Clomipramine and serotonin reuptake inhibitors are the mainstay of treatment for OCD. Choice of a particular agent should be based on the patient's previous response and the adverse effect profile of the drug. Pharmacokinetics should also be a consideration due to age-related changes in hepatic and renal function leading to increased plasma concentrations as well as prolonged elimination half-lives of these agents. Behavioural therapy, in addition to pharmacological management, is essential to treat compulsions and to improve response.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8601051     DOI: 10.2165/00002512-199507060-00004

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  95 in total

1.  Increased plasma tricyclic antidepressant concentrations in two patients concurrently treated with fluoxetine.

Authors:  J M Downs; A D Downs; T L Rosenthal; N Deal; H S Akiskal
Journal:  J Clin Psychiatry       Date:  1989-06       Impact factor: 4.384

2.  Elevated antidepressant plasma levels after addition of fluoxetine.

Authors:  A B Aranow; J I Hudson; H G Pope; T A Grady; T A Laage; I R Bell; J O Cole
Journal:  Am J Psychiatry       Date:  1989-07       Impact factor: 18.112

3.  Panic and phobic disorders in patients with obsessive compulsive disorder.

Authors:  L S Austin; R B Lydiard; M D Fossey; J J Zealberg; M T Laraia; J C Ballenger
Journal:  J Clin Psychiatry       Date:  1990-11       Impact factor: 4.384

4.  Paroxetine and obsessive-compulsive disorder.

Authors:  N S Kaye; C Dancu
Journal:  Am J Psychiatry       Date:  1994-10       Impact factor: 18.112

5.  Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine.

Authors:  N J Keuthen; P Cyr; J A Ricciardi; W E Minichiello; M L Buttolph; M A Jenike
Journal:  J Clin Psychopharmacol       Date:  1994-06       Impact factor: 3.153

6.  Successful treatment of obsessive-compulsive disorder with clonidine hydrochloride.

Authors:  J W Knesevich
Journal:  Am J Psychiatry       Date:  1982-03       Impact factor: 18.112

7.  Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report.

Authors:  J B Weilburg; J F Rosenbaum; J Biederman; G S Sachs; M H Pollack; K Kelly
Journal:  J Clin Psychiatry       Date:  1989-12       Impact factor: 4.384

8.  Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial.

Authors:  P Thorén; M Asberg; B Cronholm; L Jörnestedt; L Träskman
Journal:  Arch Gen Psychiatry       Date:  1980-11

9.  Obsessive-compulsive disorder.

Authors:  J S March; H Johnston; J H Greist
Journal:  Am Fam Physician       Date:  1989-05       Impact factor: 3.292

10.  Fluoxetine treatment of obsessive-compulsive disorder: an open clinical trial.

Authors:  M R Liebowitz; E Hollander; F Schneier; R Campeas; J Hatterer; L Papp; J Fairbanks; D Sandberg; S Davies; M Stein
Journal:  J Clin Psychopharmacol       Date:  1989-12       Impact factor: 3.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.